Vitro Biopharma is an innovative biotechnology company focused on developing Wharton's jelly-derived cell therapies and targeting autoimmune diseases and inflammatory disorders. Our goal is to become a leader in developing differentiated product candidates in a rapid and efficient manner for the immunology and inflammatory market. AlloRx Stem Cell therapy is intended to be an “off-the-shelf” commercialized product that is stored frozen and available for on demand use. Our pipeline includes five core development programs. We intend to initiate our clinical trials for Long COVID and PTHS in 2023 pending receipt of sufficient funding. In addition, we are also currently focused on our pre-clinical development programs for MS and Lupus/SLE.